Skip to main content
AMICUS THERAPEUTICS, INC. logo

AMICUS THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · FOLD ISIN · US03152W1099 LEI · 549300MRD1SMUTNBPQ53 US Manufacturing
Open in API
Filings indexed 1,650 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country US United States of America
Listing US FOLD

About AMICUS THERAPEUTICS, INC.

https://www.amicusrx.com/

Amicus Therapeutics, Inc. is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering advanced therapies for people living with rare and devastating diseases. The company leverages innovative technology platforms to create high-quality medicines that address unmet medical needs in human genetic disorders. Its primary areas of focus include the research and commercialization of treatments for conditions such as Fabry disease and Pompe disease. Amicus Therapeutics is committed to being at the forefront of therapeutic development for rare metabolic diseases.

Recent filings

Filing Released Lang Actions
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, reporting the completion of a merger where Amicus Therapeutics, Inc. became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. It includes details about the merger agreement, termination of a loan agreement, delisting notification to Nasdaq, changes in control, resignation and appointment of directors and officers, and amendments to the certificate of incorporation and bylaws. The document is a current report on significant corporate events, specifically a merger and related corporate governance changes. It is not a full annual or quarterly report, earnings release, or proxy statement. It is not a simple announcement of a report publication but a substantive regulatory filing reporting material corporate events. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-04-27 English
S-8 POS - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC by Amicus Therapeutics, Inc. It relates to deregistration of securities following a merger where Amicus became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The document references multiple SEC registration numbers and details the removal of unsold securities from registration. Form S-8 is used for securities registration related to employee benefit plans and equity incentive plans. This document is a regulatory filing related to capital structure changes but is not a direct capital/financing update or a share issue announcement. It is a formal SEC filing concerning registration statements and deregistration, fitting best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement but a substantive regulatory filing. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-04-27 English
S-8 POS - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC by Amicus Therapeutics, Inc. It relates to deregistration of securities following a merger where Amicus became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The document references multiple registration numbers and equity incentive plans, and it is a formal SEC filing concerning securities registration and deregistration. Form S-8 is used for registering securities to be offered under employee benefit plans. This document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration and deregistration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (8728 characters) and content confirm it is a substantive regulatory filing, not a brief announcement or certification.
2026-04-27 English
S-8 POS - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC by Amicus Therapeutics, Inc. It relates to deregistration of securities following a merger where Amicus became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The document primarily deals with the removal of unsold securities from registration under the S-8 forms, which are used for employee benefit plans and equity incentive plans. This is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive amendment information. Therefore, the appropriate classification is Transaction in Own Shares (POS), as it involves deregistration of securities related to equity incentive plans and employee stock purchase plans, which falls under share repurchase/issuance or related capital changes.
2026-04-27 English
S-8 POS - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC. It relates to deregistration of securities following a merger where Amicus Therapeutics became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The document is a regulatory filing concerning the termination of securities offerings and removal of unsold securities from registration. It is not a financial report, earnings release, or presentation but a formal SEC filing about securities registration status. The form type S-8 and the content about deregistration and post-effective amendments clearly indicate this is a Transaction in Own Shares or Capital Change related filing. However, Form S-8 amendments and deregistration notices are best classified under Transaction in Own Shares (POS) as they relate to share registration and deregistration. The document length is 8728 characters, sufficient for a full filing, not just an announcement. Therefore, the most appropriate classification is POS (Transaction in Own Shares).
2026-04-27 English
S-8 POS - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC by Amicus Therapeutics, Inc. It relates to deregistration of securities following a merger where Amicus became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The document is a regulatory filing concerning securities registration and deregistration, specifically related to equity incentive plans and stock purchase plans. It is not a financial report, earnings release, or management discussion. It is a formal SEC filing updating registration statements and removing unsold securities from registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 8728 characters, which is substantive and contains detailed regulatory information, not just an announcement or certification. Hence, the classification is RNS with high confidence.
2026-04-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.